Verubulin

维卢布林

Report date: 2025/01/08 10:37:37
NME

Base Information

Drug NameVerubulin
Drug Alias NameVerubulinumVerubulinaVeribulinAzixaMX-128495 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin polymerisation inhibitors
TargetsTubulin
Therapy Area/IndicationsSolid tumoursNeurodegenerative DiseasesAmyotrophic Lateral Sclerosis +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmune Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesColumbia University
Inactive CompaniesMyrexis Inc
Active IndicationsNeurodegenerative DiseasesAmyotrophic Lateral SclerosisAlzheimer Disease
Inactive IndicationsSolid tumoursBrain NeoplasmsMelanoma +[4] 

Other Information

ATC CodeN/A
Related LinksKEGG